Sol-Gel Reports First Quarter 2024 Financial Results and Provides Corporate Updates

May 20, 2024

https://www.globenewswire.com/news-release/2024/05/20/2884749/0/en/Sol-Gel-Reports-First-Quarter-2024-Financial-Results-and-Provides-Corporate-Updates.html

NESS ZIONA, Israel, May 20, 2024 (GLOBE NEWSWIRE) — Sol-Gel Technologies, Ltd. (NASDAQ:SLGL), a dermatology company, pioneering treatments for patients with severe skin conditions, conducting a Phase 3 clinical trial of SGT-610 (patidegib gel, 2%) for Gorlin syndrome, and with two approved large-category dermatology products, TWYNEO® and EPSOLAY®, today announced financial results for the first quarter ended March 31, 2024 and provided a corporate update.

Read more at globenewswire.com

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.